---
document_datetime: 2025-11-12 16:00:04
document_pages: 19
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lutathera-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: lutathera-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 11.8862575
conversion_datetime: 2025-12-28 02:56:53.467643
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## LUTATHERA

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                               |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------|
| II/0058              | To update sections 4.2, 4.8, 5.1, 5.2 and 11 of the SmPC to update the efficacy and safety information based on primary analysis results from study CAAA601A32201 (NETTER-P) as well as results from modelling and simulation analysis of PK and dosimetry data of Lutathera in adolescents. NETTER- | 21/10/2025                          | 03/11/2025                                  | SmPC and PL                      | Please refer to Scientific Discussion 'Lutathera-H-C- 004123-II-0058' |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | P study is a Phase II, multicenter open-label study which evaluated the safety and dosimetry of Lutathera in adolescent patients with somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and pheochromocytoma and paragangliomas (PPGLs). The package leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                          |            |     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0060/G | This was an application for a group of variations. B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.a - Change in batch size (including batch size | 12/03/2025 | n/a |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| ranges) of AS or intermediate increase compared to the size B.I.b.2.e - Change in test starting material/reagent/intermediate changes to a test procedure or addition) for the AS or material/intermediate B.I.b.2.e - Change in test starting material/reagent/intermediate changes to a test procedure or addition) for the AS or material/intermediate B.I.b.2.e - Change in test starting material/reagent/intermediate changes to a test procedure or addition) for the AS or material/intermediate B.I.d.1.a.4 - Stability of period/storage period - re-test period/storage period data B.II.b.z - Change in manufacture Product - Other variation B.II.b.3.a - Change in the the finished or intermediate in the manufacturing process B.II.b.4.a - Change in the size ranges) of the finished compared to the originally B.I.a.3.d - Change in batch   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | compared to the originally approved batch                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |    | increase size   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------|
| N/0059    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                    | 10/01/2025 | 23/04/2025 | PL |                 |
| IB/0057/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other | 10/01/2025 | n/a        |    | variation       |
| N/0056    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                    | 26/09/2024 | 23/04/2025 | PL |                 |
| IB/0054/G | This was an application for a group of variations. B.II.e.z - Change in container closure system of the Finished Product - Other variation B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                                                                                                                             | 18/09/2024 | n/a        |    |                 |
| IB/0055   | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting                                                                                                                                                                                                                                                                                                                                                                                                                                 | 11/09/2024 | n/a        |    |                 |

<div style=\"page-break-after: always\"></div>

|           | material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |             |                        |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------|
| IA/0053/G | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor test procedure | 05/08/2024 | n/a        |             | changes to an approved |
| IB/0051   | B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 24/05/2024 | n/a        |             |                        |
| II/0048   | B.I.a.1.g - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new manufacturer of the AS that is not supported by an ASMF and requires significant update to the relevant AS section in the dossier                                                                                                                                                                                                                                                                                                                | 02/05/2024 | 23/04/2025 | SmPC and PL |                        |
| IA/0050/G | This was an application for a group of variations. B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                | 20/03/2024 | n/a        |             |                        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | - Administrative change - Deletion of sites - Changes in the manufacturing process of AS - Minor change in the manufacturing process the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |    | A.7 manufacturing B.I.a.2.a the of   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|--------------------------------------|
| N/0049    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 19/03/2024 | 23/04/2025 | PL |                                      |
| IA/0047/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS | 11/12/2023 | n/a        |    | B.I.a.2.a - Changes                  |

<div style=\"page-break-after: always\"></div>

|           | the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process   |            |     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0046/G | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 04/12/2023 | n/a |

<div style=\"page-break-after: always\"></div>

|                     | A.7 - Administrative change - Deletion of manufacturing sites B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.z - Quality change - Active substance - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation   |            |            |    |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------------------------|
| N/0045              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                            | 19/09/2023 | 25/01/2024 | PL |                                   |
| IB/0044/G           | This was an application for a group of variations. B.I.a.3.z - Change in batch size (including batch size ranges) of AS or intermediate - Other variation B.II.b.4.z - Change in the batch size (including batch size ranges) of the finished product - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                    | 19/09/2023 | n/a        |    |                                   |
| PSUSA/10643 /202212 | Periodic Safety Update EU Single assessment - lutetium (177Lu) oxodotreotide                                                                                                                                                                                                                                                                                                                                                                                | 06/07/2023 | n/a        |    | PRAC Recommendation - maintenance |
| IB/0043             | B.I.c.1.c - Change in immediate packaging of the AS - Liquid ASs (non sterile)                                                                                                                                                                                                                                                                                                                                                                              | 16/05/2023 | n/a        |    |                                   |

<div style=\"page-break-after: always\"></div>

| II/0038   | Update of sections 2, 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 4.9, 5.1, 5.2, 5.3, 6.2, 6.4, 6.5, 6.6, 11 and 12 of the SmPC to align the Lutathera product information to the latest Core Data Sheet (CDS) version 2.0 (changes to the CDS based on data from the Lutathera existing dossier, current medical practice and new literature). Annex IIIA and the package leaflet are updated accordingly. In addition, additional corrections and changes are made throughout the product information (PI) to comply with the latest QRD template and to improve the language. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | 20/04/2023   | 25/01/2024   | SmPC and PL            | SmPC new text • Most of the changes were made to the posology and method of administration and instructions for preparation of radiopharmaceuticals: clarification that there is a 1 week flexibility in the interval between each administration; changes to the recommendation regarding hydration and urination during treatment to reduce toxicity risk; clarification that permanent discontinuation is needed in case of adverse reactions requiring dosing interval beyond 16 weeks; new text to allow physicians to perform infusion of the amino acid solution in the same arm as Lutathera, while infusion in different arms remain the preferred method; a footnote in the dose modification table clarifying that lymphopenia is not a dose modifying toxicity; introduction and description of the syringe pump method when delivering a reduced dose of Lutathera • Recommendation on the duration of contraception after the last dose of Lutathera was revised: -from 6 moths to 7 months for female patients -from 6 months to 4 months for male patients • Information regarding the time of occurrence on platelet nadir and recovery was introduced to the adverse reaction section. • Recommendation that Lutathera should not be   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0041 | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 10/02/2023   | 25/01/2024   | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| IB/0040             | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                    | 19/01/2023   | n/a        |                       |                                                                                                                                                                                                                                                                         |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10643 /202112 | Periodic Safety Update EU Single assessment - lutetium (177Lu) oxodotreotide                                                                                                                                                                                                                                                                                                                                                                                                  | 21/07/2022   | 26/09/2022 | SmPC and PL           | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10643/202112.                                                                                                                              |
| R/0032              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                       | 19/05/2022   | 08/07/2022 | SmPC, Annex II and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of LUTATHERA in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IB/0037/G           | This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.z - Change in the batch size (including batch size ranges) of the finished product - Other variation | 27/06/2022   | n/a        |                       |                                                                                                                                                                                                                                                                         |
| IB/0034             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                              | 21/04/2022   | n/a        |                       |                                                                                                                                                                                                                                                                         |
| IB/0035/G           | This was an application for a group of variations. B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other                                                                                                                                                                                                                                                                                                                              | 12/04/2022   | n/a        |                       |                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| changes to a test procedure does not have a significant quality of the AS B.I.z - Quality change variation B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.a.2.e - Changes in the AS - Minor change ASMF B.I.a.2.a - Changes in the AS - Minor change of the AS B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.I.a.1.f - Change in the starting material/reagent/intermediate Changes to quality control the AS -replacement or batch control/testing takes B.I.c.2.b - Change in the and/or limits of the immediate Addition of a new specification specification with its corresponding B.I.a.3.a - Change in ranges) of AS or intermediate   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | size                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                        |                                                                                                                                                                                                                                                                 |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0030   | Update of the SmPC sections 4.4, 4.8, 5.1 based on the pivotal Phase III study, NETTER-1. Additionally, updates are proposed in the PI to correct some information based on currently approved data. The MAH also took the opportunity to add some minor editorial changes in the PI. The PL is updated accordingly. The MAH took also the opportunity to update the details of all local representatives in the PL. The RMP v. 2.0 has been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 24/03/2022 | 08/07/2022 | SmPC, Labelling and PL | This variation implements updated long term efficacy and safety clinical information following the completion of study Netter-1 the pivotal study object of the initial approval. For more information, please refer to the Summary of Product Characteristics. |
| IA/0033/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                         | 09/02/2022 | 08/07/2022 | Annex II and PL        |                                                                                                                                                                                                                                                                 |
| IA/0031   | B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised                                                                                                                                                                                                                                                                                                                                       | 04/10/2021 | n/a        |                        |                                                                                                                                                                                                                                                                 |
| IB/0029   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 16/07/2021 | n/a        |                        |                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|                     | re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10643 /202012 | Periodic Safety Update EU Single assessment - lutetium (177Lu) oxodotreotide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 08/07/2021 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IA/0028             | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 31/03/2021 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0022             | Update of sections 4.2, 4.4, 4.5, 4.6, 4.8 and 5.1 of the SmPC in order to introduce structural changes in the dosing and administration and warnings and precautions section, include clarifications in the pregnancy and overdose sections, update instructions for use based on end user feedback and update of amino acid solution information based on review and approval of LysaKare; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to include correction of typographical errors and editorial changes in the PI in line with the latest QRD template version 10.1. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 10/12/2020 | 21/01/2021 | SmPC, Annex II and PL | Management of severe or intolerable adverse drug reactions may require temporary dose interruption, extending dosing interval from 8 weeks up to 16 weeks, dose reduction, or discontinuation of treatment with Lutathera. Treatment with Lutathera in patients with creatinine clearance < 40 mL/min at baseline (using Cockcroft Gault) is not recommended. No dose adjustment is recommended for renally impaired patients with creatinine clearance ≥ 40 mL/min. However, as this medicinal product is known to be substantially excreted by the kidneys, renal function should be more frequently monitored during the treatment as these patients may be at a greater risk of toxicity. The pharmacokinetic profile of lutetium (177Lu) oxodotreotide in patients with severe hepatic impairment has not been studied (total bilirubin > 3 times upper limit of normal and any ASAT), therefore those patients should only be treated with Lutathera after careful benefit-risk assessment. The recommended infusion method for administration of Lutathera is the gravity method. Addition of specific warnings and precautions in SmPC |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |     | section 4.4 regarding the co-administered renal protective amino acid solution. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10643 /202006 | Periodic Safety Update EU Single assessment - lutetium (177Lu) oxodotreotide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 14/01/2021 | n/a | PRAC Recommendation - maintenance                                                                                                                               |
| IA/0026             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 04/12/2020 | n/a |                                                                                                                                                                 |
| IA/0025/G           | This was an application for a group of variations. B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 04/12/2020 | n/a |                                                                                                                                                                 |
| IB/0024/G           | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                      | 13/10/2020 | n/a |                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|                     | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |             |                                                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| II/0021/G           | This was an application for a group of variations. B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold | 03/09/2020 | n/a        |             |                                                                                                                                            |
| PSUSA/10643 /201912 | Periodic Safety Update EU Single assessment - lutetium (177Lu) oxodotreotide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 09/07/2020 | n/a        |             | PRAC Recommendation - maintenance                                                                                                          |
| PSUSA/10643 /201906 | Periodic Safety Update EU Single assessment - lutetium (177Lu) oxodotreotide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 30/01/2020 | 01/04/2020 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10643/201906. |
| IA/0020             | B.II.b.2.a - Change to importer, batch release                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 23/03/2020 | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|           | and quality control testing of the FP - of a site where batch takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |     | arrangements Replacement/addition control/testing   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------|
| IB/0018/G | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change process                                                                                                                                                                                                                                                                                                                                       | 12/02/2020 | n/a | in the manufacturing                                |
| IB/0017/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold the originally approved batch size | 24/12/2019 | n/a | compared to                                         |
| IB/0015/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 14/08/2019 | n/a |                                                     |

<div style=\"page-break-after: always\"></div>

|                     | B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size   |            |            |      |                                                                                                                                                                                                                                                                                                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10643 /201812 | Periodic Safety Update EU Single assessment - lutetium (177Lu) oxodotreotide                                                                                                                                                                                                                                                                                                                                                                                  | 11/07/2019 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                 |
| IB/0014             | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                          | 19/06/2019 | n/a        |      |                                                                                                                                                                                                                                                                                                                   |
| IB/0013             | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                           | 07/06/2019 | n/a        |      |                                                                                                                                                                                                                                                                                                                   |
| IA/0012             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                              | 15/04/2019 | n/a        |      |                                                                                                                                                                                                                                                                                                                   |
| II/0005             | Update of the SmPC section 5.1 to include information on the quality of life based on relevant analyses of NETTER-I study data. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance                                                                                                                                                                                                                  | 31/01/2019 | 25/03/2019 | SmPC | Health Related Quality of Life (HRQOL) was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) (generic instrument) and its neuroendocrine tumour module (EORTC QLQ-GI.NET-21). The results indicate an improvement in the overall global |

<div style=\"page-break-after: always\"></div>

|                     | data                                                                                                                                                                                                           |            |            |                            | health-related quality of life up to week 84, for patients on Lutathera treatment as compared to patients on Octreotide LAR arm.   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------|------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10643 /201806 | Periodic Safety Update EU Single assessment - lutetium (177Lu) oxodotreotide                                                                                                                                   | 17/01/2019 | n/a        |                            | PRAC Recommendation - maintenance                                                                                                  |
| N/0008              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                               | 17/12/2018 | 25/03/2019 | PL                         |                                                                                                                                    |
| IB/0007             | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                            | 05/12/2018 | n/a        |                            |                                                                                                                                    |
| PSUSA/10643 /201712 | Periodic Safety Update EU Single assessment - lutetium (177Lu) oxodotreotide                                                                                                                                   | 12/07/2018 | n/a        |                            | PRAC Recommendation - maintenance                                                                                                  |
| IAIN/0004           | B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer | 18/05/2018 | n/a        |                            |                                                                                                                                    |
| IAIN/0003           | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                     | 21/03/2018 | 25/03/2019 | Annex II, Labelling and PL |                                                                                                                                    |
| IB/0001             | B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method                  | 21/02/2018 | n/a        |                            |                                                                                                                                    |